Europe — EMA

Ogivri (Trastuzumab)

Request sourcing

Pack/s

What is Trastuzumab?

Trastuzumab, the active ingredient in Ogivri, is a monoclonal antibody presented as a solution for infusion for intravenous use. It treats HER2‑positive breast cancer and HER2‑positive gastric cancer in adult patients. GNH USA supplies Ogivri as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Ogivri as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Trastuzumab used for?

Ogivri is a targeted therapy used in HER2‑driven cancers. It is indicated for: - HER2‑positive breast cancer: improves survival and reduces disease recurrence. - HER2‑positive gastric cancer: slows the progression of the disease. - HER2‑positive metastatic metastatic disease of the stomach and gastro‑intestinal tract : - ... ... ...

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →